News coverage about Concord Medical Services (NYSE:CCM) has trended somewhat positive recently, according to Accern. Accern rates the sentiment of media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Concord Medical Services earned a news impact score of 0.02 on Accern’s scale. Accern also gave news coverage about the company an impact score of 46.8424924271348 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Separately, Zacks Investment Research upgraded shares of Concord Medical Services from a “hold” rating to a “buy” rating and set a $4.50 price target for the company in a research report on Friday, September 22nd.
Concord Medical Services (CCM) traded up $0.07 during midday trading on Friday, hitting $3.79. 16,966 shares of the stock were exchanged, compared to its average volume of 14,380. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.60 and a quick ratio of 1.59. Concord Medical Services has a 52 week low of $3.22 and a 52 week high of $4.96.
Concord Medical Services Holdings Limited is engaged in the leasing of radiotherapy and diagnostic imaging equipment, the provision of management services to hospitals. The Company is also engaged in hospital operations. The Company’s segments are network and premium cancer hospital. The Company operates a network of radiotherapy and diagnostic imaging centers in China.
Receive News & Ratings for Concord Medical Services Holdings Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concord Medical Services Holdings Limited and related companies with MarketBeat.com's FREE daily email newsletter.